卡瑞利珠单抗联合卡铂和培美曲塞一线治疗晚期非鳞状非小细胞肺癌:CameL 3期试验延长随访
CameL 3期研究延长随访(最短43.9个月)显示,卡瑞利珠单抗联合卡铂和培美曲塞较单纯化疗显著改善晚期非鳞状非小细胞肺癌总生存(中位27.1个月 vs 19.8个月,HR=0.72,95%CI 0.57-0.92)。化疗组95例(45.9%)交叉接受卡瑞利珠单抗单药,校正后HR=0.55(95%CI 0.42-0.71)。联合组33例完成2年卡瑞利珠单抗治疗,客观缓解率97.0%,安全性特征与既往报告一致。
要点
- 卡瑞利珠单抗联合化疗较单纯化疗显著改善总生存:中位27.1个月 vs 19.8个月,HR=0.72(95%CI 0.57-0.92)。
- 化疗组95例(45.9%)交叉至卡瑞利珠单抗单药,校正后HR=0.55(95%CI 0.42-0.71)。
- 联合组33例完成2年卡瑞利珠单抗治疗,客观缓解率97.0%,其中17/32例缓解持续(53.1%)。
核心结论
- 卡瑞利珠单抗联合卡铂和培美曲塞较单纯化疗为晚期非鳞状非小细胞肺癌提供长期生存获益,毒性可控,完成2年卡瑞利珠单抗治疗的患者缓解显著且持久,进一步支持该联合方案作为一线治疗。
研究设计与样本
- CameL 3期研究(ClinicalTrials.gov: NCT03134872),患者按1:1随机接受4至6周期卡瑞利珠单抗联合卡铂和培美曲塞或单纯化疗(每3周),随后维持卡瑞利珠单抗联合培美曲塞或仅培美曲塞(n=205和207)。
- 卡瑞利珠单抗总暴露时间最长2年,自末例患者随机化起最短随访43.9个月。
主要发现
- 截至2022年1月31日,卡瑞利珠单抗联合化疗组较单纯化疗组总生存显著改善:中位27.1个月 vs 19.8个月,HR=0.72(95%CI 0.57-0.92)。
- 化疗组95例(45.9%)交叉接受卡瑞利珠单抗单药治疗;校正交叉后,联合组生存获益更明显:校正HR=0.55(95%CI 0.42-0.71)。
- 联合组33例完成2年卡瑞利珠单抗治疗,客观缓解率97.0%,32例缓解者中17例(53.1%)缓解持续,33例中31例(93.9%)在数据截止时存活。
- 安全性特征与既往报告一致,长期暴露于卡瑞利珠单抗未发现明显累积毒性证据。
临床怎么用
- 作者认为,卡瑞利珠单抗联合卡铂和培美曲塞可作为晚期非鳞状非小细胞肺癌的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In CameL phase 3 study (ClinicalTrials.gov: NCT03134872), addition of camrelizumab to first-line chemotherapy significantly improved the progression-free survival in patients with stages IIIB to IV nonsquamous NSCLC. Here, we present outcomes after a minimum follow-up of 43.9 months since last patient randomization. METHODS: Eligible patients were randomized 1:1 to 4 to 6 cycles of camrelizumab plus carboplatin and pemetrexed or chemotherapy alone every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only (n = 205 and 207, respectively). Total camrelizumab exposure was up to 2 years. RESULTS: As of January 31, 2022, camrelizumab plus chemotherapy exhibited substantially improved overall survival over chemotherapy alone (median, 27.1 versus 19.8 mo; hazard ratio = 0.72 [95% confidence interval: 0.57-0.92]). In the chemotherapy-alone group, 95 patients (45.9%) crossed over to camrelizumab monotherapy. After adjustment for crossover, the survival benefit with camrelizumab plus chemotherapy was more pronounced (adjusted hazard ratio = 0.55 [95% confidence interval: 0.42-0.71]). In camrelizumab plus chemotherapy group, 33 patients completed 2 years of camrelizumab. Objective response rate was 97.0%, with ongoing responses in 17 of the 32 responses (53.1%), and 93.9% (31 of 33) of the patients were alive at data cutoff. Safety profiles were consistent with the previous report, and no obvious evidence of cumulative toxicity was found with long exposure to camrelizumab. CONCLUSIONS: Camrelizumab plus carboplatin and pemetrexed provides long-term survival benefit over chemotherapy, with manageable toxicity and remarkable and durable response in patients receiving 2 years of camrelizumab, further supporting camrelizumab combination as first-line treatment for advanced nonsquamous NSCLC.
引用
- Zhou C, Chen G, Huang Y, et al. Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial. J Thorac Oncol. 2023. PMID: 36646210. doi:10.1016/j.jtho.2022.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。